Compare Charles Schwab Corporation Common Stock (SCHW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs BIO-TECHNE Corp — how do they compare? Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 14.7× BIO-TECHNE Corp's market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.32%). Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and BIO-TECHNE Corp for 64 Days on average.
| SCHW | TECH | |
|---|---|---|
Market Cap | $167.52B | $11.36B |
Volume | 6,554,126 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $113.65 | $72.61 |
52-Week Low | $85.35 | $43.31 |
Typical Hold Time | 85 Days | 64 Days |
Enterprise Value | $153.97B | $11.39B |
Dividend Yield | 1.32% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.87, up 1.35% on the day, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.62 exceeding the $1.56 estimate. Revenue for 2025 reached $23.92 billion, driving a net income margin of 38.79%. Analyst consensus is bullish with a $120.33 price target, and recent news highlights growth in client assets and AI integration for advisors.
The outlook remains positive given strong profitability and market share gains, though technical weakness and interest rate sensitivity pose near-term risks. Earnings momentum and strategic initiatives like the Texas Stock Exchange listing support upside potential, but investors should monitor competitive pressures and macroeconomic volatility.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
